The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism

Current Opinion in Drug Discovery and Development

Volumn 9, Issue 1, 2006, Pages 101-109

  Fisher, Michael B ^a   Henne, Kirk R ^b   Boer, Jason ^c  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b AMGEN INC   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

ADME; CYP; Cytochrome P450; Deuterium; Metabolism; Metabolite

Indexed keywords

3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; 4 CYCLOPROPYLETHYNYL 5,6 DIFLUORO 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; BENZYLAMINE DERIVATIVE; CYTOCHROME P450; DEUTERIUM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FLUORINE; FLUORINE 18; FLUOROPYRROLIDINE DERIVATIVE; HYDROGEN; ISOTOPE; N,N DIMETHYL 2 (2 AMINO 5 FLUOROPHENYLTHIO)BENZYLAMINE F 18; PYRROLIDINE DERIVATIVE; RADIOLIGAND; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; CATALYSIS; CATALYST; CHEMICAL REACTION; DEUTERATION; DISSOCIATION; DRUG CLEARANCE; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; FLUORINATION; GENE DUPLICATION; METABOLIC CLEARANCE RATE; NONHUMAN; REACTION ANALYSIS; REVIEW; STRUCTURE ANALYSIS;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DEUTERIUM; DRUG DESIGN; ENZYME INHIBITORS; FLUORINE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SUBSTRATE SPECIFICITY;

EID: 30744467708     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, Wrighton SA: Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods (2000) 44(1):313-324.
2. Smith D, Schmid E, Jones B: Do drug metabolism and pharmacokinetic departments make any contribution to drug discovery? Clin Pharmacokinet (2002) 41(13):1005-1019.
3. Eddershaw PJ, Beresford AP, Bayliss MK: ADME/PK as part of a rational approach to drug discovery. Drug Disc Today (2000) 5(9):409-414.
4. van de Waterbeemd H, Smith DA, Jones BC: Lipophilicity in PK design: Methyl, ethyl, futile. J Comput Aided Mol Des (2001) 15(3):273-286. Describes the influence of physical properties, mostly lipophilicity, on the ADME properties of drugs, with an emphasis on central nervous system drugs.
5. Lewis DF, Dickins M: Substrate SARs in human P450s. Drug Disc Today (2002) 7(17):918-925. Describes the physical properties of substrates for various CYP isoforms, including a decision tree approach to predict isoform selectivity.
6. Lewis DF, Jacobs MN, Dickins M: Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Disc Today (2004) 9(12):530-537.
7. van de Waterbeemd H, Smith DA, Beaumont K, Walker DK: Property-based design: Optimization of drug absorption and pharmacokinetics. J Med Chem (2001) 44(9):1313-1333.
8. Obach RS: The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discovery Dev (2001) 4(1):36-44. Provides an excellent summary of the conduct and assumptions inherent in predicting in vivo clearance from in vitro liver microsome lability data.
9. Zhang ZY, Kerr J, Wexier RS, Li HY, Robinson AJ, Harlow PP, Kaminsky LS: Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarln 7-hydroxylation. Thromb Res (1997) 88(4):389-398.
10. Ojima I, Inoue T, Chakravarty S: Enantiopure fluorine-containing taxoids: Potent anticancer agents and versatile probes for biomedical problems. J Fluorine Chem (1999) 398(1-2):3-10.
11. Helfenbein J, Lartigue C, Noirault E, Azim E, Legailliard J, Galmier MJ, Madelmont JC: Isotopic effect study of propofol deuteration on the metabolism, activity and toxicity of the anesthetic. J Med Chem (2002) 45(26):5806-5808.
12. Gillette JR: The Pennsylvania State University College of Medicine 1991 Bernard B Brodle Lecture. Insights into deuterium isotope effects on the metabolism of steroid hormones and foreign compounds by cytochrome P-460 enzymes. Life Sci (1991) 49(1):1-14.
13. Cook DL, Atkins VvM: Enhanced detoxication due to distributive catalysis and toxic thresholds: A kinetic analysis. Biochemistry (1997) 36(36):10801-10808. Discusses the behavior of xenobiotic-metabolizing enzymes and proposes a provocative driving force for this evolution.
14. Nelson DR: Cytochrome P450 and the individuality of species. Arch Biochem Biophys (1999) 369(1):1-10.
15. Atkins WM, Lu WD, Cook DL: Is there a toxicological advantage for non-hyperbolic kinetics in cytochrome P450 catalysis? Functional allostery from "distributive catalysis". J Biol Chem (2002) 277(36):33258-33266.
16. The Jones Lab: Exploring the bioorganic chemistry of drug metabolism: Washington State University, Pullman, WA, USA. http://joneslab.wsu.edu/
17. Lee H, Ortiz de Montellano PR, McDermott AE: Deuterium magic angle spinning studies of substrates bound to cytochrome P450. Biochemistry (1999) 38(33):10808-10813.
18. cam Biochemistry (2002) 41(49):14499-14508.
19. Jung C: Cytochrome P-460-CO and substrates: Lessons from ligand binding under high pressure. Biochim Biophys Acta (2002) 1595(1-2):309-328.
20. Modi S, Gilham DE, Sutcliffe MJ, Lian L-Y, Primrose WU, Wolf CR, Roberts GC: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: Allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry (1997) 36(15):4461-4470.
21. 1) relaxation measurements. Arch Biochem Biophys (2000) 384(1):47-58.
22. Hummel MA, Gannet PM, Aguilar JS, Tracy TS: Effector-mediated alteration of substrate orientation in cytochrome P450 2C9. Biochemistry (2004) 43(22):7207-7214.
23. Poli-Scaife S, Attias R, Dansette PM, Mansuy D: The substrate binding site of human liver cytochrome P450 2C9: An NMR study. Biochemistry (1997) 36(42):12672-12682.
24. cam. J Am Chem Soc (1995) 117(10):2738-2746.
25. cam and its L244A mutant. J Am Chem Soc (1997) 119(24):5489-5498.
26. cam. J Inorg Biochem (2000) 81(3):121-131.
27. Jencks WP: Isotope effects. In: Catalysis in Chemistry and Enzymology. Dover Publications Inc, Mineola, NY, USA (1987):243-281.
28. cam: Kinetic evidence for the two-electron reduction of high-valent iron-oxo intermediate. Biochemistry(1988) 27(5):1610-1616.
29. Denisov IG, Makris TM, Sligar SG: Cryotrapped reaction intermediates of cytochrome P450 studied by radiolytic reduction with phosphorus-32. J Biol Chem (2001) 276(15):11648-11652.
30. Higgins L, Bennett GA, Shimoji M, Jones JP: Evaluation of cytochrome P450 mechanism and kinetics using kinetic deuterium isotope effects. Biochemistry (1998) 37(19):7039-7046. Provides a thorough overview of the use of kinetic deuterium isotope effects to examine cytochrome P450 reactions and enzymatic behavior.
31. 6-testosterone from testosterone. Drug Metab Dispos (1990) 18(6):974-979.
32. Jones JP, Korzekwa KR, Rettie AE, Trager WF: Isotopically sensitive branching and its effect on the observed intramolecular isotope effects in cytochrome P-450 catalyzed reactions: A new method for the estimation of intrinsic isotope effects. J Am Chem Soc (1986) 108(22):7074-7078. This paper, and subsequent papers by these authors, made key contributions to the application and understanding of isotope effect experiments to cytochrome P450 reactions.
33. Gillette JR, Korzekwa KR: Overview: Theoretical aspects of isotope effects on the pattern of metabolites formed by cytochrome P-450. In: Biological Reactive Intermediates IV: Advances in experimental Medicine and Biology. Witmer CM, Synder RR, Jollow DJ. Kalf GF, Kocsis JJ (Eds), Plenum Press, New York, NY, USA (1990):87-94.
34. Iyer KR, Jones JP, Derbyshire JF, Trager WF: Intramolecular isotope effects for benzylic hydroxylation of isomeric xylenes and 4,4′- dimethylbiphenyl by cytochrome P450: Relationship between distance of methyl groups and masking of the intrinsic isotope effect. Biochemistry (1997) 36(23):7136-7143. Describes an interesting application of intramolecular isotope effect masking to elucidate isoform differences in active site volume.
35. Audergon C, Iyer KR, Jones JP, Darbyshire JF, Trager WF: Experimental and theoretical study of the effect of the active-site constrained substrate motion on the magnitude of the observed intramolecular isotope effect for the P450 101 catalyzed benzylic hydroxylation of isomeric xylenes and 4,4′- dlmethylbiphenyl. J Am Chem Soc (1999) 121(1):41-47.
36. Henne KR, Fisher MB, Iyer KR, Lang DH, Trager WF, Rettie AE: Active site characteristics of CYP4B1 probed with aromatic ligands. Biochemistry (2001) 40(29):8597-8605.
37. Obach RS: Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs. Drug Metab Dispos (2001) 29(12):1599-1607.
38. Wust M, Croteau RB: Hydroxylation of specifically deuterated limonene enantiomers by cytochrome P450 limonene 6-hydroxylase reveals the mechanism of multiple product formation. Biochemistry (2002) 41(6):1820-1827.
39. Gorsky LD, Koop DR, Coon MJ: On the stoichiometry of the oxidase and monooxygenase reactions catalyzed by liver microsomal cytochrome P-450. J Biol Chem (1984) 269(11):6812-6817.
40. McMahon RE, Culp HW, Craig JC, Ekwuribe N: Mechanism of the dealkylation of tertiary amines by hepatic monooxygenases. Stable isotope studies wtth 1-benzyl-4-cyano-phenylpiperidine. J Med Chem (1979) 22(9):1100-1103.
41. Nelson SD, Pohl LR, Trager WF: Primary and β-secondary deuterium isotope effects in N-deethylatlon reactions. J Med Chem (1975) 18(11):1062-1065.
42. Mamanda K, Kasuya Y, Baba S: Pharmacokinetic equivalence of deuterium-labeled and unlabeled phenytoin. Drug Metab Dispos (1986) 14(4):509-511.
43. Nelson SD, Trager WF: The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. Drug Metab Dispos (2003) 31(12):1481-1498. Provides a thorough review of the use of deuterium isotope effects in metabolism and bioactivation studies.
44. Böhm H-J, Banner D, Bendels S, Kansy M, Kuhn B, Müller K, Obst-Sander U, Stahl M: Fluorine in medicinal chemistry. ChemBioChem (2004) 5(5):637-643.
45. Guengerich FP: Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res 7oxicol(2001) 14(6):611-650. Provides an excellent and exhaustive review of CYP bioactivation reactions.
46. Scarfe GB, Tugnait M, Wilson ID, Nicholson JK: Studies on the metabolism of 4-fluoroaniline and 4-fluoroacetanilide in rat: Formation of 4-acetamidophenol (paracetamol) and its metabolites via defluorination and N-acetylation. Xenobiotica (1999) 29(2):205-216.
47. McKillop D, McCormick AD, Miles GS, Phillips PJ, Pickup KJ, Bushby N, Hutchinson M: In vitro metabolism of gefltinib in human liver microsomes. Xenobiotica (2004) 34(11-12):983-1000.
48. McKillop D, Hutchinson M, Partridge EA, Bushby N, Cooper CM, Clarkson-Jones JA, Herron W, Swaisland HC: Metabolic disposition of gefltinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica (2004) 34(10):917-934.
49. 18F]-ADAM) as a serotonin transporter imaging agent. Appl Radiat Isot (2004) 61(6):1247-1254.
50. 18F-ADAM): An improved PET radioligand for serotonin transporters. J Nucl Med (2003) 44(12):1890-1897.
51. Chen H, Shockor J, Chen W, Espina R, Gan L-S, Mutlib AE: Delineating novel metabolic pathways of DPC 963, a non-nucleoside reverse transcriptase inhibitor, in rats. Characterization of glutathione conjugates of postulated oxirene and benzoquinone imine intermediates by LC/MS and LC/NMR. Chem Res Toxicol (2002) 16(3):388-399.
52. Samuel K, Yin W, Steams RA, Tang YS, Chaudhary AG, Jewell JP, Lanza T, Lin LS, Hagmann WK, Evans DC, Kumar S: Addressing the metabolic activation potential of new leads in drug discovery: As case study using ion trap mass spectrometry and tritium labeling techniques. J Mass Spectrom (2003) 38(2):211-221.
53. Xu S, Zhu B, Teffera Y, Pan DE, Caldwell CG, Doss G, Steams RA, Evans DC, Beconi MG: Metabolic activation of fluoropyrrolidine dipeptidyl peptidase-IV inhibitors by rat liver microsomes. Drug Metab Dispos (2005) 33(1):121-130.
54. Zhang D, Krishna R, Wang L, Zeng J, Mitroka J, Dai R, Narasimhan N, Reeves RA, Srinivas NR, Klunk LJ: Metabolism, pharmacokinetics and protein covalent binding of radiolabeled Maxipost (BMS-204352) in humans. Drug Metab Dispos (2005) 33(1):83-93.
55. Atkinson JK, Hollenberg PF, Ingold KU, Johnson CC, Le Tadic M-H, Newcomb M, Putt DA: Cytochrome P450-catalyzed hydroxylation of hydrocarbons: Kinetic deuterium isotope effects for the hydroxylation of an ultrafast radical clock. Biochemistry (1994) 33(35):10630-10637.